National Resilience acquired the Triangle office in 2021. Since then, funding for gene therapy solutions has fallen.
XyloCor Therapeutics Inc., a Wayne gene therapy company, received $67.5 million from investors to support Phase 2 trials of a treatment designed to grow new blood vessels in the heart, XyloCor ...
A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...
The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...
Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...
Bryan Johnson, who’s spending hundreds of millions of dollars on treatments designed to extend his life, is many things to ...
A new study published in the peer-reviewed journal Human Gene Therapy involved the generation of a human monoclonal antibody ...